Champions Oncology, Inc. (CSBR) shareholders
CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026Score 9/30246% above fair value
$4.71+0.05 (+1.18%)
Close on Nov 13, 2026Market cap $65.49MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
42.4%
6M of 14M shares
Institutional holders
28
4 new, 1 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Anthony A. Florence, Jr. | 1,713,720 | – | 13D (active) amendment | Mar 15, 2024 |
| Morgan Duke Joint filing with West Elk Partners, LP (6.49%), West Elk, LLC (6.49%) and 2 more | 882,581 | 6.49% | 13G (passive) amendment | Sep 30, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CSBR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Battery Management Corp. | 2,421,673 | 17.40% | $14.92M | – | 4.05% |
| NEA Management Company, LLC | 1,713,720 | 12.31% | $10.56M | – | 0.66% |
| Vanguard Capital Management LLC | 301,353 | 2.17% | $1.86M | +1,833 | 0.00% |
| Tocqueville Asset Management L.P. | 295,658 | 2.12% | $1.82M | −24,016 | 0.02% |
| Morgan Stanley | 235,400 | 1.69% | $1.45M | −6,900 | 0.00% |
| Bank Of America Corp /De/ | 214,058 | 1.54% | $1.32M | +192,225 | 0.00% |
| Renaissance Technologies LLC | 139,039 | 1.00% | $856.48K | −6,500 | 0.00% |
| BlackRock, Inc. | 129,848 | 0.93% | $799.86K | +5,948 | 0.00% |
| Mink Brook Asset Management LLC | 111,338 | 0.80% | $685.84K | – | 0.30% |
| Geode Capital Management, LLC | 76,300 | 0.55% | $470.12K | −877 | 0.00% |
| HighTower Advisors, LLC | 41,901 | 0.30% | $258.11K | +6,743 | 0.00% |
| Vanguard Fiduciary Trust Co | 33,239 | 0.24% | $204.75K | +247 | 0.00% |
| Northern Trust Corp | 27,910 | 0.20% | $171.93K | −18,022 | 0.00% |
| State Street Corp | 26,203 | 0.19% | $161.41K | – | 0.00% |
| Cambridge Investment Research Advisors, Inc. | 24,504 | 0.18% | $150.00K | +12,252 | 0.00% |
| Bank of New York Mellon Corp | 21,614 | 0.16% | $133.14K | – | 0.00% |
| Acadian Asset Management LLC | 20,523 | 0.15% | $125.00K | −800 | 0.00% |
| Citadel Advisors LLC | 18,295 | 0.13% | $112.70K | New | 0.00% |
| Essex Investment Management Co LLC | 18,221 | 0.13% | $112.24K | −28 | 0.01% |
| Mesirow Financial Investment Management, Inc. | 15,800 | 0.11% | $97.33K | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 28 | 6M | 42.4% | 4 / 6 | 7 / 1 | 0M | 0M |
| Q1 2026 | 25 | 6M | 41.2% | 4 / 5 | 6 / 5 | 0M | 0M |
| Q4 2025 | 27 | 6M | 41.3% | 3 / 7 | 8 / 3 | 0M | 0M |
| Q3 2025 | 27 | 6M | 40.7% | 2 / 5 | 10 / 5 | 0M | 0M |
| Q2 2025 | 30 | 6M | 41.5% | 4 / 8 | 7 / 8 | 0M | 0M |
| Q1 2025 | 34 | 6M | 42.5% | 10 / 10 | 6 / 1 | 0M | 0M |
| Q4 2024 | 25 | 6M | 41.1% | 6 / 6 | 4 / 3 | 0M | 0M |
| Q3 2024 | 22 | 6M | 41.6% | 3 / 7 | 3 / 3 | 0M | 0M |
| Q2 2024 | 23 | 6M | 41.5% | 0 / 6 | 8 / 2 | 0M | 0M |
| Q1 2024 | 25 | 6M | 41.1% | 5 / 6 | 9 / 3 | 0M | 0M |
| Q4 2023 | 23 | 6M | 40.4% | 0 / 8 | 7 / 5 | 0M | 0M |
| Q3 2023 | 29 | 6M | 41.2% | 3 / 4 | 10 / 2 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
21 funds held CSBR in Q2 2026, 78% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CSBR | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 229,971 | 1.65% | $1.42M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 62,775 | 0.45% | $386.69K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 32,203 | 0.23% | $188.39K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 28,454 | 0.20% | $175.28K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 12,140 | 0.09% | $71.02K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 10,958 | 0.08% | $64.10K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 9,232 | 0.07% | $54.01K | 0.00% | May 31, 2026 |
| Schwab Total Stock Market Index Fund | 6,854 | 0.05% | $36.74K | 0.00% | Jul 31, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 6,527 | 0.05% | $40.21K | 0.00% | Jun 30, 2026 |
| Small Cap Core Fund | 4,471 | 0.03% | $27.54K | 0.01% | Jun 30, 2026 |
| Vanguard Balanced Index Fund | 2,080 | 0.01% | $12.81K | 0.00% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 2,034 | 0.01% | $12.53K | 0.01% | Jun 30, 2026 |
| LVIP Dimensional U.S. Core Equity 2 Fund | 279 | 0.00% | $1.72K | 0.00% | Jun 30, 2026 |
| JNL/DFA U.S. Small Cap Fund | 149 | 0.00% | $918 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Robert Lawrence Brainin | CEO, Director | – | – | Jan 30, 2026 |
| David Sidransky | Director | 767,043 | 5.51% | Nov 9, 2026 |
| Scott R. Tobin | Director, 10% owner | 2,041,882 | 14.67% | Nov 9, 2026 |
| Joel Ackerman | Director | 1,126,333 | 8.09% | Nov 9, 2026 |
| Daniel Newman Mendelson | Director | 298,625 | 2.15% | Nov 9, 2026 |
| Philip P. Breitfeld | Director | 5,717 | 0.04% | Nov 7, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Joel Ackerman Director | Oct 15, 2026 | Option exercise | +69,794 | $1.60 | $111.67K | 1,126,333 |
| Joel Ackerman Director | Oct 30, 2025 | Option exercise | +94,405 | $2.10 | $198.25K | 1,056,539 |
| Philip P. Breitfeld Director | Mar 25, 2025 | Other | −4,150 | – | – | 5,717 |
| Joel Ackerman Director | Oct 31, 2024 | Option exercise | +88,470 | $2.10 | $185.79K | 945,467 |
| Joel Ackerman Director | Oct 31, 2024 | Option exercise | +16,667 | $5.43 | $90.50K | 962,134 |
| Daniel Newman Mendelson Director | Jan 12, 2024 | Buy | +1,000 | $6.50 | $6.50K | 198,625 |
| Daniel Newman Mendelson Director | Jan 11, 2024 | Buy | +2,000 | $6.27 | $12.54K | 197,625 |
| Daniel Newman Mendelson Director | Jan 10, 2024 | Buy | +2,944 | $6.31 | $18.58K | 195,625 |
| Daniel Newman Mendelson Director | Jan 9, 2024 | Buy | +3,000 | $6.25 | $18.75K | 192,681 |
| Daniel Newman Mendelson Director | Jan 8, 2024 | Buy | +1,000 | $6.15 | $6.15K | 189,681 |
| Daniel Newman Mendelson Director | Jan 5, 2024 | Buy | +2,000 | $6.09 | $12.18K | 188,681 |
| Daniel Newman Mendelson Director | Jan 4, 2024 | Buy | +3,000 | $6.12 | $18.36K | 186,681 |
| Daniel Newman Mendelson Director | Jan 3, 2024 | Buy | +500 | $5.83 | $2.92K | 183,681 |
| Daniel Newman Mendelson Director | Dec 21, 2023 | Buy | +2,500 | $4.92 | $12.30K | 183,181 |
| Daniel Newman Mendelson Director | Dec 20, 2023 | Buy | +2,100 | $4.82 | $10.12K | 180,681 |
| Daniel Newman Mendelson Director | Dec 19, 2023 | Buy | +5,000 | $4.75 | $23.75K | 178,581 |
| Joel Ackerman Director | Oct 17, 2023 | Option exercise | +114,552 | $2.10 | $240.56K | 856,997 |
| Daniel Newman Mendelson Director | Oct 11, 2023 | Buy | +5,000 | $6.40 | $32.00K | 163,081 |
| Daniel Newman Mendelson Director | Oct 10, 2023 | Buy | +1,100 | $6.41 | $7.05K | 158,081 |
| Daniel Newman Mendelson Director | Oct 6, 2023 | Buy | +1,530 | $6.48 | $9.91K | 156,981 |
| Daniel Newman Mendelson Director | Oct 5, 2023 | Buy | +2,000 | $6.47 | $12.94K | 155,451 |
| Daniel Newman Mendelson Director | Oct 4, 2023 | Buy | +5,000 | $6.40 | $32.00K | 153,451 |
| Daniel Newman Mendelson Director | Oct 3, 2023 | Buy | +2,500 | $6.30 | $15.75K | 148,451 |
| Daniel Newman Mendelson Director | Sep 29, 2023 | Buy | +4,000 | $6.16 | $24.64K | 173,581 |
| Daniel Newman Mendelson Director | Sep 28, 2023 | Buy | +5,000 | $6.22 | $31.10K | 169,581 |
| Daniel Newman Mendelson Director | Sep 27, 2023 | Buy | +1,500 | $5.95 | $8.93K | 164,581 |
| Daniel Newman Mendelson Director | Sep 26, 2023 | Buy | +5,000 | $5.65 | $28.25K | 145,951 |
| Daniel Newman Mendelson Director | Sep 22, 2023 | Buy | +3,812 | $5.50 | $20.97K | 140,951 |
| Daniel Newman Mendelson Director | Sep 21, 2023 | Buy | +5,000 | $5.51 | $27.55K | 137,139 |
| Daniel Newman Mendelson Director | Sep 20, 2023 | Buy | +4,018 | $5.51 | $22.14K | 132,139 |
| Daniel Newman Mendelson Director | Sep 19, 2023 | Buy | +5,000 | $5.28 | $26.40K | 128,121 |
| Ronnie Morris CEO, Director | Mar 17, 2023 | Buy | +12,382 | $4.04 | $50.02K | 858,878 |
| Joel Ackerman Director | Oct 19, 2022 | Option exercise | +16,667 | $3.21 | $53.50K | 1,460,595 |
| David Sidransky Director | Oct 12, 2022 | Tax withholding | −3,562 | $7.51 | $26.75K | 767,043 |
| David Sidransky Director | Oct 12, 2022 | Option exercise | +8,333 | $3.21 | $26.75K | 770,605 |
| Philip P. Breitfeld Director | Oct 12, 2022 | Option exercise | +8,333 | $3.21 | $26.75K | 18,200 |
| Philip P. Breitfeld Director | Oct 12, 2022 | Tax withholding | −3,562 | $7.51 | $26.75K | 14,638 |
| Scott R. Tobin Director | Oct 12, 2022 | Option exercise | +10,000 | $3.21 | $32.10K | 30,000 |
| David Sidransky Director | Oct 15, 2021 | Tax withholding | +2,629 | $10.08 | $26.50K | 762,272 |
| David Sidransky Director | Oct 15, 2021 | Option exercise | +16,667 | $1.59 | $26.50K | 764,901 |
| Scott R. Tobin Director | Oct 12, 2021 | Option exercise | +10,000 | $1.59 | $15.90K | 20,000 |
| Philip P. Breitfeld Director | Mar 23, 2021 | Option exercise | +4,167 | $3.65 | $15.21K | 4,167 |
| Philip P. Breitfeld Director | Mar 23, 2021 | Tax withholding | −1,340 | $11.35 | $15.21K | 2,827 |
| Abba David Poliakoff Director | Jan 19, 2021 | Option exercise | +10,000 | $3.21 | $32.10K | 80,147 |
| Abba David Poliakoff Director | Jan 19, 2021 | Option exercise | +10,000 | $5.43 | $54.30K | 90,147 |
| Abba David Poliakoff Director | Jan 19, 2021 | Option exercise | +10,000 | $1.59 | $15.90K | 70,147 |
| Abba David Poliakoff Director | Jan 19, 2021 | Tax withholding | +8,873 | $11.53 | $102.31K | 81,274 |
| Philip P. Breitfeld Director | Dec 16, 2020 | Sale | −31,443 | $11.35 | $356.88K | 0 |
| Scott R. Tobin Director | Oct 30, 2020 | Option exercise | +10,000 | $5.46 | $54.60K | 10,000 |
| David Sidransky Director | Oct 16, 2020 | Tax withholding | −10,100 | $9.01 | $91.00K | 748,234 |
| David Sidransky Director | Oct 16, 2020 | Option exercise | +16,667 | $5.46 | $91.00K | 758,334 |
| Daniel Newman Mendelson Director | Mar 26, 2020 | Buy | +100 | $5.99 | $599 | 57,646 |
| Daniel Newman Mendelson Director | Mar 26, 2020 | Buy | +20 | $6.00 | $120 | 57,546 |
| Daniel Newman Mendelson Director | Mar 26, 2020 | Buy | +700 | $5.90 | $4.13K | 58,446 |
| Daniel Newman Mendelson Director | Mar 26, 2020 | Buy | +100 | $5.97 | $597 | 57,746 |
| Daniel Newman Mendelson Director | Mar 26, 2020 | Buy | +300 | $5.89 | $1.77K | 58,746 |
| Daniel Newman Mendelson Director | Mar 24, 2020 | Buy | +26 | $5.50 | $143 | 57,526 |
| Ronnie Morris CEO, Director | Mar 24, 2020 | Sale | −75 | $5.25 | $394 | 837,168 |
| Ronnie Morris CEO, Director | Mar 20, 2020 | Buy | +75 | $4.75 | $356 | 837,243 |
| Ronnie Morris CEO, Director | Mar 11, 2020 | Option exercise | +2,708 | $4.80 | $13.00K | 964,108 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
0.75%
0M shares short
Days to cover
8.6
At 0M shares a day
Change since last report
-6.9%
From 0M shares
Short volume, 20 days
34.3%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Champions Oncology's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.
See a number that looks wrong?